

Trattamenti sperimentali per Covid-19 in Italia

Data ultimo aggiornamento: 27 luglio 2020

Intervention	Database	ID	Title	Acronym
ABX464	AIFA	2020-001673-75	MIR-AGE - ABX464 A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failure in patients aged = 65 and patients aged =18 with at least one additional risk factor who are infected with SARS-CoV-2. (the MIR-AGE study)	MIR-AGE
Acalabrutinib	AIFA	2020-001644-25	ACE-ID-201-Acalabrutinib Studio randomizzato, in aperto, di Fase II sull'efficacia e la sicurezza di Acalabrutinib in associazione alle migliori terapie di supporto rispetto alle sole migliori terapie di supporto in soggetti ricoverati con COVID-19.	ACE-ID-201
Anakinra	AIFA	2020-001167-93	Sobi.IMMUNO-101 emapalumb and anakinra versus standard of care	Sobi.IMMUNO-101
Baricitinib	AIFA	2020-001854-23	BARCIVID Studio sull'utilizzo di baricitinib	BARCIVID
	Clinicaltrials.gov	NCT04358614	AMMURAVID Studio di fase 3 multiarm della SIMIT	AMMURAVID
Bevacizumab	Clinicaltrials.gov	NCT04421027	Baricitinib Therapy in COVID-19	COV-BARRIER
	Clinicaltrials.gov	NCT04275414	A Study of Baricitinib (LY3009104) in Participants With COVID-19	BEST-CP
Canakinumab	AIFA	2020-001370-30	Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia	CAN-COVID
	AIFA	2020-001854-23	CAN-COVID - Studio sull'utilizzo di Canakinumab	CAN-COVID
Chloroquine	AIFA	2020-001366-11	AMMURAVID Studio di fase 3 multiarm della SIMIT	AMMURAVID
	AIFA	2020-001475-33	SOLIDARITY - Studio randomizzato OMS	SOLIDARITY
Colchicine	AIFA	2020-001258-23	COLVID-19 Studio randomizzato sull'utilizzo di colchicina	COLVID-19
	AIFA	2020-001806-42	ColCOVID Studio sull'utilizzo di colchicina	ColCOVID
Convalescent plasma	Clinicaltrials.gov	NCT04385043	Home CarE study Colchicina	CHOICE-19
	Clinicaltrials.gov	NCT04428021	Hyperimmune Plasma in Patients With COVID-19 Severe Infection	COV2-CP
	Clinicaltrials.gov	NCT04321421	Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure	PLACO-COVID
	Clinicaltrials.gov	NCT04346589	Hyperimmune Plasma for Critical Patients With COVID-19	COV19-PLASMA
	Clinicaltrials.gov	NCT04393727	Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients	
	Clinicaltrials.gov	NCT04418531	Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19	TSUNAMI
Darunavir/ cobicistat	AIFA	2020-001528-32	Convalescent Antibodies Infusion in COVID 19 Patients	LIFESAVER
DAS181	Clinicaltrials.gov	NCT04354389	Early transfusion of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.	
Defibrotide	AIFA	2020-001513-20	ARCO Studio multi-arm di gestione domiciliare	ARCO
	AIFA	2020-001167-93	DAS181 for STOP COVID-19	
Enoxaparin	AIFA	2020-001708-41	DEF-IVID19 - Studio sull'utilizzo di defibrotide	DEF-IVID19
	AIFA	2020-001972-13	Sobi.IMMUNO-101 emapalumb and anakinra versus standard of care	Sobi.IMMUNO-101
	AIFA	2020-001308-40	X-COVID Studio sull'utilizzo di Enoxaparina per la tromboprofilassi di pazienti ospedalizzati COVID-19	X-COVID
	AIFA	2020-002214-40	Studio sull'utilizzo di eparina a basso peso	COVID-19 HD
Enoxaparin+Methylprednisolone	AIFA	2020-001921-30	INHIXACOVID Studio sull'utilizzo di enoxaparina	INHIXACOVID
	AIFA	2020-001528-32	EMOS-COVID - Enoxaparina	EMOS-COVID
Eparin+Methylprednisolone	AIFA	2020-001921-30	STAUNCH - Studio sull'utilizzo di steroidi e eparina	STAUNCH
	AIFA	2020-001921-30	STAUNCH - Studio sull'utilizzo di steroidi e eparina	STAUNCH
Favipiravir	AIFA	2020-001528-32	ARCO Studio multi-arm di gestione domiciliare	ARCO
	AIFA	2020-001115-25	HS216C17 Studio di fase 3 sull'utilizzo di favipiravir	HS216C17
	AIFA	2020-001441-39	COP-COV Studio sull'utilizzo di idrossiclorochina in profilassi	COP-COV
	AIFA	2020-001987-28	PRECOV Idrossiclorochina negli operatori sanitari	PRECOV
	AIFA	2020-001501-24	PROTECT Studio sull'utilizzo di idrossiclorochina	PROTECT
	AIFA	2020-001558-23	Hydro-Stop - somministrazione precoce di idrossiclorochina	Hydro-Stop
Hydroxychloroquine	AIFA	2020-001528-32	ARCO Studio multi-arm di gestione domiciliare	ARCO
	AIFA	2020-001366-11	SOLIDARITY - Studio randomizzato OMS	SOLIDARITY
	AIFA	2020-001802-50	AZI-RCT-COVID-19 - Studio sull'utilizzo di idrossiclorochina+azitromicina	AZI-RCT-COVID-19
Hydroxychloroquine+Azitromycin	AIFA	2020-001366-11	SOLIDARITY - Studio randomizzato OMS	SOLIDARITY
	AIFA	2020-002458-25	INTERCOP - Interferone-beta Studio randomizzato, controllato, in aperto, di fase 2 con Interferone-β-1a (IFNβ-1a) in pazienti con COVID-19	INTERCOP
Ivermectin	Clinicaltrials.gov	NCT04438850	COVidIVERmectin: Ivermectin for Treatment of Covid-19	COVER
Lopinavir/Ritonavir	AIFA	2020-001528-32	ARCO Studio multi-arm di gestione domiciliare	ARCO
	AIFA	2020-001366-11	SOLIDARITY - Studio randomizzato OMS	SOLIDARITY
Mavrilimumab	AIFA	2020-001795-15	COMBAT-19 Studio sull'utilizzo di mavrilimumab	COMBAT-19
Methylprednisolone	AIFA	2020-001854-23	AMMURAVID Studio di fase 3 multiarm della SIMIT	AMMURAVID
Nafamostat Mesilate	Clinicaltrials.gov	NCT04352400	Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)	RACONA
Oxytocin	Clinicaltrials.gov	NCT04386447	Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19	OscCOVID19
Pamrevlumab	AIFA	2020-001472-14	FibroCov - Studio di fase 2/3 sull'utilizzo di Pamrevlumab	FibroCov
Polyvalent Immunoglobulin	AIFA	2020-002058-26	High dose intravenous polyvalent immunoglobulin in patients with early inflammatory COVID-19	IVIG/H/Covid-19
Prasugrel Hydrochloride	Clinicaltrials.gov	NCT04445623	Prasugrel in Severe COVID-19 Pneumonia	PARTISAN
	AIFA	2020-000842-32	GS-US-540-5774 Study: Remdesivir in Participants with Moderate COVID-19	GS-US-540-5774
Remdesivir	AIFA	2020-000841-15	GS-US-540-5773 Study: Remdesivir in Participants with Severe COVID-19	GS-US-540-5773
	AIFA	2020-001366-11	SOLIDARITY - Studio randomizzato OMS	SOLIDARITY
Reparixin	AIFA	2020-001645-40	REPAVID-19 - Studio di fase 2/3 su reparixin	REPAVID-19
Ruxolitinib	Clinicaltrials.gov	NCT04362137	Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)	RUXCOVID
Sarilumab	AIFA	2020-001390-76	ESCAPE Studio di fase 2 sull'utilizzo di sarilumab	ESCAPE
	AIFA	2020-001162-12	Sarilumab COVID-19 Sarilumab for hospitalized patients with COVID-19	Sarilumab COVID-19
	AIFA	2020-001854-23	AMMURAVID Studio di fase 3 multiarm della SIMIT	AMMURAVID
Selinexor	AIFA	2020-001745-40	COVID-SARI Studio sull'utilizzo di sarilumab	COVID-SARI
	AIFA	2020-001411-25	XPORT-CoV-1001 Studio di fase 2 sull'utilizzo di Selinexor	XPORT-CoV-1001
Siltuximab	AIFA	2020-001854-23	AMMURAVID Studio di fase 3 multiarm della SIMIT	AMMURAVID
Sitagliptin	Clinicaltrials.gov	NCT04365517	The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients	SIDIACO
Tirofiban	Clinicaltrials.gov	NCT04368377	Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19	PIC-19
	AIFA	2020-001110-38	Studio TOCIVID-19	TOCIVID-19
	AIFA	2020-001386-37	RCT-TCZ-COVID-19 somministrazione precoce del Tocilizumab	RCT-TCZ-COVID-19
Tocilizumab	AIFA	2020-001154-22	Tocilizumab 2020-001154-22 Tocilizumab in patients with severe COVID-19 pneumonia	Tocilizumab 2020-001154-22
	AIFA	2020-001854-23	AMMURAVID Studio di fase 3 multiarm della SIMIT	AMMURAVID
Tofacitinib	Clinicaltrials.gov	NCT04315480	Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis	
	AIFA	2020-002035-30	TOFACOV-2 - Studio sull'utilizzo di Tofacitinib	TOFACOV-2
Vitamin C (intravenously)	Clinicaltrials.gov	NCT04323042	TOFActinib in SARS-CoV2 Pneumonia	
	Clinicaltrials.gov	NCT04323514	Use of Ascorbic Acid in Patients With COVID 19	